Two thousand dollars vs $89 000. That is the cost of deflazacort per year before and after the recent US Food and Drug Administration (FDA) approval for symptomatic treatment in Duchenne muscular dystrophy (DMD).1 On February 9, 2017, the FDA granted approval for labeled use of deflazacort to mitigate DMD symptoms.2 Prior to its approval in the United States, deflazacort had been available overseas for decades; in accordance to the Federal Food, Drug, and Cosmetic Act,3 it was then legal to obtain it overseas. (Briefly, this law states that patients are allowed to import foreign drugs if several criteria are met, including an absence of commercialization in the United States.) After the domestic approval and commercialization of deflazacort, it is now illegal to purchase foreign deflazacort, which was previously affordably priced.
Chrzanowski SM, Poudyal R. Deflazacort—New Costs of an Old Medicine. JAMA Neurol. 2018;75(2):143–144. doi:10.1001/jamaneurol.2017.3704
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: